Insider Selling: Glaukos (NYSE:GKOS) Director Sells 15,000 Shares of Stock

by · The Markets Daily

Glaukos Corporation (NYSE:GKOS – Get Free Report) Director Aimee Weisner sold 15,000 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the transaction, the director owned 18,806 shares in the company, valued at $2,207,448.28. This trade represents a 44.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Glaukos Stock Performance

NYSE:GKOS remained flat at $120.27 during mid-day trading on Monday. The company had a trading volume of 665,667 shares, compared to its average volume of 863,185. The company has a market capitalization of $6.91 billion, a PE ratio of -36.89 and a beta of 0.70. The company has a 50 day moving average price of $115.30 and a 200 day moving average price of $99.01. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a one year low of $73.16 and a one year high of $130.69.

Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm’s revenue was up 35.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.40) earnings per share. Research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently made changes to their positions in GKOS. Smartleaf Asset Management LLC raised its holdings in shares of Glaukos by 9.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after acquiring an additional 122 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. CWM LLC boosted its holdings in Glaukos by 25.2% in the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock valued at $80,000 after acquiring an additional 143 shares in the last quarter. Commonwealth Equity Services LLC increased its position in Glaukos by 1.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after purchasing an additional 144 shares during the period. Finally, Evergreen Capital Management LLC raised its holdings in Glaukos by 4.3% in the 4th quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 145 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GKOS has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a research note on Wednesday, January 14th. BTIG Research reiterated a “buy” rating and issued a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. William Blair upgraded Glaukos to a “strong-buy” rating in a report on Friday, January 30th. The Goldman Sachs Group restated a “buy” rating and set a $138.00 price target on shares of Glaukos in a research report on Friday, January 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $133.69.

View Our Latest Analysis on GKOS

About Glaukos

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Read More